BNB PLUS Business Summary

BNB PLUS CORP. (BNBX) operates a dual-business model that integrates a high-yield digital asset treasury with a legacy biotechnology manufacturing segment. The company generates revenue primarily through its BNB-focused treasury strategy, which utilizes native staking, Binance Launchpool participation, PancakeSwap liquidity provision, and collateralized DeFi strategies to accumulate and compound BNB holdings. Simultaneously, its subsidiary LineaRx, Inc. commercializes the proprietary LineaDNA platform, generating revenue through the enzymatic production of synthetic DNA and RNA for biopharmaceutical and diagnostic applications. BNB PLUS CORP. competes with MicroStrategy (MSTR) in the digital asset treasury space, and Bionano Genomics (BNGO), Inotiv (NOTV), and Pharma-Bio Serv (PBSV) in the life sciences sector. The company distinguishes itself as a unique hybrid vehicle, offering regulated U.S. public market exposure to the Binance ecosystem while maintaining a specialized biotech revenue stream. The leadership team is led by President and CEO Clay Shorrock, Esq., an intellectual property expert who previously served as the company’s Chief Legal Officer and President of LineaRx. The digital asset strategy is spearheaded by Chief Investment Officer Patrick Horsman, CFA, a co-founder of Coral Capital and Verified Organic with extensive experience in DeFi and systematic trading. The board is chaired by Josh Kruger, founder of OnChain Alpha and former Head of Trading at DNA Asset Management, who brings deep expertise in blockchain-native capital efficiency. Notable strategic support includes advisor Anthony Scaramucci of SkyBridge Capital and institutional backing from Off the Chain Capital and Sabby Management. The board also features independent directors such as James Haft, a pioneer in digital asset infrastructure, and Dr. Yacov Shamash, ensuring a blend of traditional corporate governance and emerging technology expertise.